Osong Public Health and Research Perspectives,
Год журнала:
2022,
Номер
13(2), С. 84 - 100
Опубликована: Апрель 27, 2022
The
coronavirus
disease
2019
(COVID-19)
pandemic
rapidly
spread
globally.
Severe
acute
respiratory
syndrome
2
(SARS-CoV-2),
which
causes
COVID-19,
is
a
positive-sense
single-stranded
RNA
virus
with
reported
fatality
rate
ranging
from
1%
to
7%,
and
people
immune-compromised
conditions,
children,
older
adults
are
particularly
vulnerable.
Respiratory
failure
cytokine
storm-induced
multiple
organ
the
major
of
death.
This
article
highlights
innate
adaptive
immune
mechanisms
host
cells
activated
in
response
SARS-CoV-2
infection
possible
therapeutic
approaches
against
COVID-19.
Some
potential
drugs
proven
be
effective
for
other
viral
diseases
under
clinical
trials
now
use
Examples
include
inhibitors
RNA-dependent
polymerase
(remdesivir,
favipiravir,
ribavirin),
protein
synthesis
(ivermectin,
lopinavir/ritonavir),
fusion
membrane
(chloroquine,
hydroxychloroquine,
nitazoxanide,
umifenovir).
also
presents
intellectual
groundwork
ongoing
development
vaccines
preclinical
trials,
explaining
candidates
(live
attenuated-whole
vaccines,
inactivated
subunit
DNA-based
protein-based
nanoparticle-based
virus-like
particles
mRNA-based
vaccines).
Designing
developing
an
vaccine
(both
prophylactic
therapeutic)
would
long-term
solution
most
way
eliminate
COVID-19
pandemic.
The Iraqi Journal of Veterinary Medicine,
Год журнала:
2023,
Номер
47(1), С. 38 - 43
Опубликована: Июнь 28, 2023
In
the
treatment
of
COVID-19,
antiviral
medication
Favipiravir
has
proven
to
be
quite
successful.
Its
metabolism
is
mediated
by
enzymes
aldehyde
oxidase
(AO)
and
xanthine
(XO).
This
research
investigated
potential
drug-drug
interaction
betweenfavipiravir
amlodipine
in
hypertensive
rabbits.
Twenty
local
adult
male
rabbits
(aged
between
10
12
months
weighing
2
2.5
kg)
were
induced
with
hypertension
20
mg/kg
BW
desoxycorticosterone
acetate
subcutaneously
for
three
weeks
then
divided
randomly
into
two
groups
ten.
The
first
group
received
a
single
oral
dose
40
favipiravir,
while
second
5
orally
14
consecutive
days
inhibit
AO
before
receiving
favipiravir.
Blood
samples
collected
from
marginal
ear
vein
at
15,
30,
45
min,
1,
2,
4,
8,
12,
24,
48,
36,
72
h.
High-performance
liquid
chromatography
(HPLC)
was
used
determine
concentration
favipiravir
plasma.
results
showed
that
co-administration
prolonged
time
taken
(Tmax)
reach
maximum
plasma
(Cmax)
decreased
its
elimination
half-life,
increasing
area
under
curve
(AUC).
Amlodipine
also
reducing
clearance
per
unit
(Cl/f).
Additionally,
potentiated
effect
on
absorption,
distribution,
metabolism,
excretion
conclusion,
concomitant
use
other
drugs
affect
enzyme
activity
may
alter
pharmacokinetic
profile
drug.
Therefore,
adjusting
administered
patients
recommended.
Abstract:
Background:
Patients
with
diabetes
are
particularly
susceptible
to
COVID-19
infection,
which
can
result
in
severe
respiratory
illness.
Methods:
This
study
conducted
a
comparative
as-sessment
of
the
impact
antiviral
therapy
using
molnupiravir
and
favipiravir
pa-tients
underlying
diabetes.
A
cohort
one
hundred
individuals
infected
SARS-CoV-2,
diagnosed
diabetes,
consecutively
admitted,
was
included
present
study.
These
patients
were
treated
antivirals
according
local
guidelines:
Group
F
(51
cases)
–
10
days
M
(49
5
days.
Re-sults:
In
F,
average
hospitalization
higher
than
(11.29±2.27
vs.
7.14±3.16,
p
ScienceAsia,
Год журнала:
2024,
Номер
50(3), С. 1 - 1
Опубликована: Янв. 1, 2024
An
in
vitro
study
of
Thai
medicinal
plants
revealed
anti-SARS-CoV-2
activity
ethanolic
extract
Boesenbergia
rotunda
and
its
bioactive
component
panduratin
A.
The
present
aims
to
evaluate
the
safety
after
28
consecutive
days
oral
doses
according
OECD
GLP
407.The
28-day
repeated
were
performed
both
male
female
Wistar
rats.Three
150,
300
600
mg/kg/day
assigned
as
low,
medium
high
doses,
respectively.During
administration
period,
there
was
no
evidence
morbidity,
mortality,
or
neurological
toxicity
for
gender
all
doses.Weight
food
water
intake
similar
control
group.The
hematological
clinical
biochemistry
parameters
within
normal
ranges
rats.The
oestrous
cycle
animals
groups
vaginal
cytology
investigation
showed
abnormal
cellular
types.The
statistically
significant
difference
weight
organs
no-test
itemrelated
effects
histopathological
examination
remarkable
lesion.The
observed
adverse
effect
level
(NOAEL)
B.
considered
be
mg/kg
body
per
day.These
findings
are
useful
information
developing
a
potential
phytopharmaceutical
product
future
investigation.
Eurasian Journal of Ecology,
Год журнала:
2024,
Номер
79(2), С. 136 - 146
Опубликована: Янв. 1, 2024
The
emergence
of
SARS-CoV-2,
the
virus
responsible
for
COVID-19
pandemic,
has
prompted
extensive
research
into
antiviral
therapeutic
interventions
aimed
at
improving
treatment
outcomes
and
clinical
parameters.
It
provides
a
concise
overview
conducted
in
this
field,
focusing
on
impact
significance
various
drugs.
By
analyzing
key
studies
trials,
it
aims
to
elucidate
efficacy
safety
profiles
drugs
such
as
remdesivir,
favipiravir,
molnupiravir,
Paxlovid
managing
COVID-19.
scientific
practical
lies
its
contribution
understanding
role
combating
SARS-CoV-2
infection.
This
knowledge
is
crucial
optimizing
strategies
patient
during
ongoing
pandemic.
Methodologically,
involves
reviewing
synthesizing
data
from
reputable
published
peer-reviewed
journals.
Key
parameters
assessed
include
viral
clearance,
mortality
rates,
hospitalization
duration,
adverse
effects
associated
with
drug
administration.
main
results
analysis
highlight
varying
impacts
different
outcomes.
For
instance,
remdesivir
shows
promise
reducing
recovery
time
mortality,
while
favipiravir
demonstrates
enhanced
clearance
but
may
cause
transient
liver
enzyme
elevations.
In
conclusion,
underscores
value
mitigating
findings
contribute
evolving
offer
insights
care
protocols.
these
informing
healthcare
professionals
policymakers
about
effective
options
cases,
ultimately
abstract
encapsulates
essential
aspects
emphasizing
scientific,
practical,
methodological
advancing
our
response
global
Osong Public Health and Research Perspectives,
Год журнала:
2022,
Номер
13(2), С. 84 - 100
Опубликована: Апрель 27, 2022
The
coronavirus
disease
2019
(COVID-19)
pandemic
rapidly
spread
globally.
Severe
acute
respiratory
syndrome
2
(SARS-CoV-2),
which
causes
COVID-19,
is
a
positive-sense
single-stranded
RNA
virus
with
reported
fatality
rate
ranging
from
1%
to
7%,
and
people
immune-compromised
conditions,
children,
older
adults
are
particularly
vulnerable.
Respiratory
failure
cytokine
storm-induced
multiple
organ
the
major
of
death.
This
article
highlights
innate
adaptive
immune
mechanisms
host
cells
activated
in
response
SARS-CoV-2
infection
possible
therapeutic
approaches
against
COVID-19.
Some
potential
drugs
proven
be
effective
for
other
viral
diseases
under
clinical
trials
now
use
Examples
include
inhibitors
RNA-dependent
polymerase
(remdesivir,
favipiravir,
ribavirin),
protein
synthesis
(ivermectin,
lopinavir/ritonavir),
fusion
membrane
(chloroquine,
hydroxychloroquine,
nitazoxanide,
umifenovir).
also
presents
intellectual
groundwork
ongoing
development
vaccines
preclinical
trials,
explaining
candidates
(live
attenuated-whole
vaccines,
inactivated
subunit
DNA-based
protein-based
nanoparticle-based
virus-like
particles
mRNA-based
vaccines).
Designing
developing
an
vaccine
(both
prophylactic
therapeutic)
would
long-term
solution
most
way
eliminate
COVID-19
pandemic.
